Home / Themes / Healthcare '25: Mental Health & Psychiatric Treatments

Healthcare '25: Mental Health & Psychiatric Treatments (open on stockthemes)

Last updated

Theme thesis · 4/5 sections · Tickers 2 with notes · 11 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Mental health treatment companies develop and deliver pharmaceutical, psychedelic-assisted, neurostimulation and clinical services intended to improve outcomes

Thesis

Mental health treatment companies develop and deliver pharmaceutical, psychedelic-assisted, neurostimulation and clinical services intended to improve outcomes in depression, anxiety, PTSD, bipolar disorder, schizophrenia, addiction and other psychiatric conditions. The theme captures emerging antidepressant mechanisms, rapid-acting neuroplastogens, established specialty psychiatric medicines, noninvasive brain stimulation and behavioral healthcare delivery networks. Growth depends on successful clinical innovation, broader treatment eligibility, reimbursement expansion, increased patient access and greater utilization of effective therapies for patients inadequately served by conventional psychiatric treatment.

Bull case

  • Positive late-stage clinical results and regulatory approvals for psilocybin, LSD-derived medicines and other rapid-acting psychiatric treatments establish new therapeutic categories for treatment-resistant depression and anxiety, potentially expanding treatment adoption and specialist psychiatric infrastructure.

  • Improved insurance coverage and growing clinical adoption of TMS, intranasal esketamine and other interventional psychiatric procedures increase patient access to alternatives when conventional antidepressants or psychotherapy provide inadequate relief.

  • Integration of virtual psychiatry, outpatient treatment centers and specialized inpatient behavioral healthcare improves patient referral pathways and expands access, while established psychiatric drug manufacturers benefit from broader diagnosis and treatment of serious mental illness.

Bear case

  • Psychedelic and novel psychiatric drug candidates may fail late-stage trials, encounter restrictive FDA requirements or require burdensome supervised administration protocols that limit commercial adoption despite promising clinical efficacy.

  • Insurance reimbursement restrictions, provider shortages, high treatment costs and limited specialist infrastructure constrain access to newer psychiatric interventions, particularly when repeated treatment visits or supervised dosing are necessary.

  • Generic psychiatric drugs, competing treatment modalities, adverse safety findings and inconsistent long-term clinical outcomes reduce pricing power and patient adoption, while behavioral-health operators face staffing costs, reimbursement pressure and regulatory scrutiny.

Overview

Hiring Trend Watchpoints

Watch for net additions in certified TMS technicians, medical assistants, and psychiatric nurse practitioners across outpatient wellness and interventional psychiatry networks, confirming capacity expansion. Track postings for market access directors, clinical billing specialists, and payer relations managers tasked with securing regional Medicare Advantage contracts and commercial prior authorizations. For tele-behavioral platforms, observe whether licensed clinician hiring matches user volume without driving margin contraction, alongside software roles focused on AI triage and clinical intake automation. Key warning signs of theme deterioration include hiring freezes for clinical specialists, reductions in clinic-level staff, elevated therapist turnover, and headcount cuts within regulatory or reimbursement teams.

Forum Watchlist

  • reddit — r/TMShigh

    Patient sentiment, clinical efficacy feedback, side effect discussions, and commercial insurance coverage approvals for NeuroStar vs BrainsWay devices

  • reddit — r/Therapistsmedium

    Clinician reimbursement complaints, tele-behavioral platform payout dynamics, and administrative burdens with insurance payers

  • reddit — r/depressionregimenshigh

    Patient shifts away from traditional SSRIs toward device-based interventions (TMS), Spravato, and psychedelic clinical trials

  • reddit — r/MindMedInvestorsClubmedium

    Retail investor and patient sentiment around psychedelic clinical milestones, pipeline trial progression, and FDA sentiment

  • forum — forum.studentdoctor.netmedium

    Practicing psychiatrist perspectives on outpatient TMS unit economics, capital equipment ROI, and interventional workflow integration

Industry Publications

  • Psychiatric News (psychnews.psychiatryonline.org) — Official publication of the American Psychiatric Association covering clinical practice guidelines, interventional psychiatry protocols, and mental health policy shifts
  • Behavioral Health Business (bhbusiness.com) — Premier trade outlet analyzing commercial behavioral health operator trends, M&A activity, private equity consolidation, and payer reimbursement trends
  • MedTech Dive (medtechdive.com) — Provides targeted reporting on FDA clearances, clinical trial data, and commercial performance across neurostimulation and mental health medtech devices
  • Fierce Healthcare (fiercehealthcare.com) — Comprehensive coverage of CMS payment rules, Medicare Advantage behavioral health benefit mandates, and digital health reimbursement dynamics
  • Neurotech Reports (neurotechreports.com) — Specialized market research and reporting covering bioelectronic medicine, transcranial magnetic stimulation, and neurotechnology industry commercialization

Second Order Trends

A notable second-order trend is the forward vertical integration between medtech manufacturers and clinic networks—such as device makers consolidating outpatient interventional sites to secure procedure volume, capture service margins, and protect against distribution churn. Concurrently, clinics are pivoting toward multi-modality interventional care, bundling TMS, esketamine/Spravato delivery, and tele-psychiatry under single managed care contracts. Digital platforms are increasingly embedding AI intake triage tools to reduce provider administrative burden and demonstrate measurable clinical outcomes required by value-based Medicare Advantage plans. Additionally, physical interventional clinics are positioning their existing operational footprints as distribution infrastructure for future commercial psychedelic therapies, anticipating eventual regulatory clearances.

Search Keywords Brand Product

  • NeuroStar
  • Deep TMS
  • H-Coil
  • Talkspace
  • MM120
  • RNS System
  • Spravato
  • NeuroStar Advanced Therapy
  • transcranial magnetic stimulation
  • interventional psychiatry
  • treatment-resistant depression
  • tele-behavioral health
  • non-pharmacological mental health
  • psychedelic medicine
  • neuromodulation devices
  • brain stimulation therapy

Search Keywords Policy Regulatory

  • Medicare Advantage mental health coverage
  • HHS alternative mental health initiatives
  • mental health parity
  • CMS behavioral health reimbursement
  • FDA breakthrough therapy psychedelics
  • TMS coverage criteria

Search Keywords Event Phrases

  • Clinical TMS Society Annual Meeting
  • American Psychiatric Association Annual Meeting
  • CMS Physician Fee Schedule update
  • FDA Psychopharmacologic Drugs Advisory Committee
  • Psych Congress

Google Trend Product Category Intent

• TMS therapy near me • Deep TMS therapy • Talkspace online therapy • NeuroStar TMS cost • BrainsWay TMS clinic

Google Trend Consumer Intent

• alternatives to antidepressants • does insurance cover TMS • TMS therapy reviews • non drug depression treatment • TMS therapy side effects

Google Trend Macro Policy Terms

• Medicare coverage for TMS • mental health parity • alternative mental health treatment • FDA psychedelic approval

Economic Data Watch

1. U.S. Bureau of Labor Statistics / FRED — Consumer Price Index for All Urban Consumers

Matchedfred · access=api · map_only

Metric/field FRED:CUUR0000SAM2 (Medical Care Services in U.S. City Average)

Cadence monthly

Why it matters Measures inflation in clinical and medical services pricing, influencing payer rate indexation and outpatient reimbursement margins for behavioral health.

Signal to watch Accelerating index growth signals expanding payer reimbursement rates and stronger outpatient pricing power.

Confidence: high

2. U.S. Bureau of Labor Statistics / FRED — Current Employment Statistics (CES)

Matchedfred · access=api · map_only

Metric/field FRED:CES6562140001 (All Employees: Outpatient Care Centers)

Cadence monthly

Why it matters Tracks clinical staffing capacity and headcount trends across outpatient facilities that purchase and operate TMS systems and deliver behavioral health therapy.

Signal to watch Sustained upward employment growth signals clinic expansion and higher patient throughput capacity.

Confidence: high

3. U.S. Bureau of Labor Statistics / FRED — Producer Price Index (PPI)

Matchedfred · access=api · map_only

Metric/field FRED:WPU117905 (Machinery and Equipment: X-Ray and Electromedical Equipment)

Cadence monthly

Why it matters Tracks manufacturer price realization and hardware cost inflation for electromedical therapy devices, including TMS consoles and coils.

Signal to watch Moderate and steady increases indicate device pricing power without severe hardware input cost pressures.

Confidence: medium

4. Centers for Medicare & Medicaid Services (CMS) — Medicare Advantage Monthly Enrollment and Penetration Reports

Not in registry

Metric/field CMS:MA_STATE_COUNTY_PENETRATION (Total MA Enrollees / Penetration Rate)

Cadence monthly

Why it matters Monitors Medicare Advantage expansion, a critical coverage mechanism expanding supplemental behavioral health telehealth and non-drug therapeutic coverage.

Signal to watch Accelerating penetration rates signal expanding addressable patient pool with integrated outpatient mental health benefits.

Confidence: high

5. Centers for Medicare & Medicaid Services (CMS) — Physician Fee Schedule (PFS) Final Rule

Not in registry

Metric/field CMS:PFS_CONVERSION_FACTOR (Conversion Factor CF_VALUE and Total RVUs for CPT 90868 Transcranial Magnetic Stimulation delivery)

Cadence event_driven

Why it matters Directly governs fee-for-service Medicare reimbursement rates per TMS treatment session, setting the commercial benchmark for provider economics.

Signal to watch Stable to increasing conversion factors and RVU valuations preserve clinic margins and support device adoption.

Confidence: high

Free Alt Data Watch

1. Centers for Disease Control and Prevention (CDC) / NCHS — Household Pulse Survey: Mental Health

Not in registry

Metric/field CDC:ANX_DEP_SYMPTOMS (Percentage of Adults Showing Symptoms of Anxiety or Depressive Disorder)

Cadence monthly

Why it matters Provides high-frequency national surveillance of depressive and anxiety symptom prevalence, driving underlying patient demand for psychiatric care.

Signal to watch Elevated or rising symptom prevalence signals expanding addressable patient population seeking clinical care.

Confidence: high

2. U.S. Food and Drug Administration (FDA) — 510(k) Premarket Notification and De Novo Database

Not in registry

Metric/field FDA:PRODUCT_CODE_QCI (Transcranial Magnetic Stimulator Cleared Submissions, Decision Date and Review Time)

Cadence monthly

Why it matters Tracks regulatory clearance velocity, new competitive device entrants, and indication expansions (e.g., adolescent MDD, OCD, addictions).

Signal to watch Approval of expanded indications expands TAM, while surge in competing cleared devices signals intensifying hardware competition.

Confidence: high

3. National Institutes of Health (NIH) / ClinicalTrials.gov — ClinicalTrials.gov Public API

Not in registry

Metric/field CLINICALTRIALS:PHASE_STATUS (Active/Recruiting Interventional Trials for Conditions: 'Treatment-Resistant Depression' OR 'Major Depressive Disorder' AND Interventions: 'Transcranial Magnetic Stimulation' OR 'LSD' OR 'Psilocybin')

Cadence monthly

Why it matters Tracks clinical trial pipeline milestones, recruitment momentum, and expansion of non-pharma / psychedelic therapy evidence.

Signal to watch Higher enrollment velocity and transition to Phase 3/pivotal status signal impending regulatory milestones for alternative therapies.

Confidence: high

4. USASpending.gov — Federal Spending Transparency API

Not in registryaccess=api

Metric/field USASPENDING:CFDA_93.242 (Mental Health Research Grants Awarded by NIMH / SAMHSA, Total Obligated Amount)

Cadence monthly

Why it matters Monitors federal grant appropriations directly funding novel non-pharmacological therapies, neuromodulation research, and digital delivery systems.

Signal to watch Rising award obligations reflect federal execution of bipartisan/administration priorities favoring alternative mental health modalities.

Confidence: medium

5. Google Trends — Search Interest Index

Not in registry

Metric/field GOOGLE_TRENDS:SEARCH_INTEREST ('TMS therapy' + 'NeuroStar' + 'BrainsWay' + 'Talkspace', Geo: US, 12-month Rolling Index)

Cadence weekly

Why it matters Provides real-time leading indicator of consumer awareness, destigmatization, and direct patient organic query intent for device therapies and telehealth.

Signal to watch Sustained upward inflection in search interest precedes patient consult inquiries and new patient initiation trends.

Confidence: medium

Paid Alt Data Watch

1. IQVIA — National Prescription Audit (NPA) & Medical Claims Analyzer

Matchediqvia_prescription_rx_data · access=file · map_only

Metric/field IQVIA:TRX_SUBSTITUTION_INDEX (Ratio of New Prescriptions NRx for SSRI/SNRI Generics vs. CPT 90867 Initial TMS Mapping Claims)

Cadence irregular

Why it matters Tests the core thesis of clinical substitution away from traditional oral psychiatric generics toward device-based neuromodulation.

Signal to watch A declining ratio reflects successful patient migration from failed drug regimens to device-based interventions.

Confidence: high

2. Definitive Healthcare — Atlas All-Payor Claims & Commercial Specialty Analytics

Not in registry

Metric/field DEFINITIVE:CPT_90868_VOLUME (Commercial and Managed Care Claim Lines for CPT 90868 Transcranial Magnetic Stimulation Treatment Delivery)

Cadence monthly

Why it matters Tracks treatment session volume and utilization rates across outpatient clinics, directly correlating with per-click device revenue and consumable usage.

Signal to watch Sequential volume acceleration confirms widening commercial payer authorization and clinic utilization.

Confidence: high

3. FAIR Health — FH Total Benchmark & Monthly Telehealth Regional Tracker

Not in registry

Metric/field FAIR_HEALTH:MENTAL_HEALTH_TELEHEALTH_PCT (Mental Health Claim Lines as a Percentage of Total Outpatient Telehealth Claims)

Cadence monthly

Why it matters Measures structural durability of telehealth market share for behavioral healthcare delivery (critical for TALK).

Signal to watch Holding above 60%+ share indicates enduring behavioral telehealth habituation and payer reimbursement stickiness.

Confidence: high

4. Sensor Tower — App Intelligence & Mobile Performance

Matchedsensor_tower_mobile_advertising_intelligence · access=file · map_only

Metric/field SENSOR_TOWER:TALKSPACE_DAU_MAU (Daily Active Users and Monthly Active Users for Talkspace Therapy App on iOS and Android)

Cadence irregular

Why it matters Provides high-frequency proxy for digital mental health platform patient engagement, active session pacing, and retention.

Signal to watch Upward trend in DAU/MAU signals active member expansion and platform engagement health ahead of earnings reports.

Confidence: medium

5. Similarweb — Web Traffic & Conversion Analytics

Matched (medium)similarweb_website_traffic_engagement · access=file · map_only

Metric/field SIMILARWEB:PROVIDER_LOCATOR_VISITS (Monthly Desktop & Mobile Unique Visits to Provider Locator / Booking Pages on neurostar.com and brainsway.com)

Cadence irregular

Why it matters Measures high-intent patient acquisition funnel traffic seeking TMS treatment centers, translating to future clinic patient flow.

Signal to watch Increasing visits to provider locators points to growing patient funnel conversion and higher utilization per installed machine.

Confidence: medium

Prediction Market Watch

1. Will the FDA approve any psychedelic substance for medical use this year?

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxfdaapprovalpsychedelic

Why it matters Directly tracks regulatory milestone timing for the medical psychedelic sector, a key catalyst for basket constituents like MindMed (MNMD) developing novel neuropsychiatry interventions.

Series key pm_fda_psychedelic_approval

2. When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxfdaapprovaldatecmps-360

Why it matters Compass COMP360 is the bellwether late-stage psilocybin program for treatment-resistant depression; approval timing directly impacts regulatory precedent, reimbursement expectations, and valuation multiples for psychedelic psychiatry peers such as MNMD.

Series key pm_fda_cmps360_approval_date

Theme Plain English
This theme captures medical technology, digital health platforms, and neuro-interventional companies benefiting from the shift toward non-pharmacological and alternative mental healthcare. Driven by supportive federal healthcare policies favoring alternatives to traditional psychiatric pharmaceuticals, these providers deliver transcranial magnetic stimulation (TMS), digital tele-behavioral therapy, neurostimulation, and novel clinical interventions. Growth is propelled by expanding Medicare Advantage reimbursement, clinical integration in outpatient settings, and rising demand for treatment-resistant depression solutions.
Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
Prescription volume trends for SSRIs vs. TMS/psychedelicsMonthlyShows substitution away from pharma to alternative interventions like STIM, MNMD.Google_Sheets
Mental health outpatient and telehealth utilization trendsMonthly / QuarterlyMeasures demand and patient access for platforms like TALK, BWAY, and NPCE.Google_Sheets
Medicare Advantage plan mental health coverage ratesAnnual / UpdatesScope of reimbursement and access for telehealth and device therapies.Google_Sheets
Upcoming Catalysts6 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
LLY_10dadbebby year end2026-10-012026-12-31European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion.This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_48d9403dlater this year2026-10-012026-12-31Readout of Foundayo Phase 3 trial in obstructive sleep apnea.Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_696cb569later this year2026-10-012026-12-31U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes.This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth.Ticker2026-08-05earnings_transcriptLLY (ticker)
LLY_cf82d1b5a few markets late in 20262026-10-012026-12-31Launch of Orforglipron in a few international markets (e.g., UAE).This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration.Ticker2026-02-04earnings_transcriptLLY (ticker)
LLY_a24ab55bDecember 7th2026-12-072026-12-07Lilly Innovation Day.This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities.Ticker2026-10-29earnings_transcriptLLY (ticker)
LLY_a075099bQ1 20272027-01-012027-03-31U.S. regulatory submission (BLA pathway) for retatrutide.This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss.Ticker2026-10-29earnings_transcriptLLY (ticker)

News

1 story tagged to this theme — Narrative Radar and editorial picks.

October 2026

Loading correlation…

Constituents

  • LLYT13.5%
    — Eli Lilly and Company
  • JNJT3
    — Johnson & Johnson
  • ACHCT3
    · no notes yet
  • ALKST3
    · no notes yet
  • AXSMT3
    · no notes yet
  • BWAYT3
    · no notes yet
  • CMPST3
    · no notes yet
  • DFTXT3
    · no notes yet
  • GHRST3
    · no notes yet
  • HELPT3
    · no notes yet
  • LFSTT3
    · no notes yet
  • STIMT3
    · no notes yet
  • UHST3
    · no notes yet